Company intelligence / Profile preview

Asha Medical

Cincinnati, Ohio, USA

Ownership: Private
Development stage: Other

Overview

Asha Therapeutics is advancing a pipeline of novel, disease-modifying therapeutics for neurodegenerative and neuromuscular diseases. Their lead candidates—ASHA-624 (a SARM1 inhibitor) and ASHA-091 (a DRP1 inhibitor)—has demonstrated robust efficacy and safety in preclinical models. Both are expected to enter first-in-human clinical trials by late 2024[3][5][6]. The company’s PRISM™ platform enables rapid de novo drug design targeting previously undruggable proteins.

Therapeutic areas: Infectious DiseasesNeurologyOncology
Modalities: Small moleculeMolecular glue therapy
Industry: Biotech

Partnerships

Johnson & Johnson Innovation - JLABS/BLUE KNIGHT™Biomedical Advanced Research and Development Authority (BARDA)CMT Research Foundation[2][8]ALS Association/Barnett Drug Development Grant[5]

Beyond the preview

Go deeper on Asha Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Asha Medical.

Explore the full profile